FindTrial
Sign In

A prospective, multicenter, randomized, open, controlled clinical study about the efficacy and safety of the 70-year-old and older Chinese acute ischemic stroke population intravenous thrombolytic therapy with different doses of alteplase

A prospective, multicenter, randomized, open, controlled clinical study about the efficacy and safety of the 70-year-old and older Chinese acute ischemic stroke population intravenous thrombolytic therapy with different doses of alteplase

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-13003024
Enrollment
Unknown
Registered
2013-01-23
Start date
2013-02-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cerebral infarction

Interventions

High dose versus low dose:alteplase 0.9mg/kg versus 0.6mg/kg for one year treatment

Sponsors

Department of Neurology, Affiliated Drum Tower Hospital of Nanjing University Medical School
Lead Sponsor

Eligibility

Sex/Gender
All
Age
70 Years to 100 Years

Inclusion criteria

Inclusion criteria: Acute ischemic stroke patients aged over 70 years in Chinese population, For intravenous thrombolytic therapy within 4.5 hours after the stroke onset, Inform consent was obtained from patients or their families.

Exclusion criteria

Exclusion criteria: The intracranial hemorrhage with CT confirmed, Very minor neurological dysfunction or rapid improvement, Someone accompanied with clear Seizures,intracranial hemorrhage after cerebral infarction, etc

Design outcomes

Primary

MeasureTime frame
Neurological function and cognitive function, the risk of recurrent stroke, complications, mortality;—

Countries

China

Contacts

Public ContactXu Yun
xuyun20042001@yahoo.com.cn+86 25 831 0-5208

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026